INKT

MiNK Therapeutics (INKT)

About MiNK Therapeutics (INKT)

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded by Garo H. Armen in 2017 and is headquartered in New York, NY.

Details

Daily high

$11.97

Daily low

$11.00

Price at open

52 Week High

$18.17

52 Week Low

$8.48

Market cap

58.3M

Dividend yield

0.00%

Volume

Avg. volume

11,948

P/E ratio

-4.12

MiNK Therapeutics News